Posted by Michael Wonder on 09 Nov 2020
Eligible patients living with rare debilitating genetic disorder are one step closer to having access to first-of-its-kind treatment option
5 November 2020 - Takeda Canada is pleased to announce it has completed the Letter of Intent with the pan Canadian Pharmaceutical Alliance for Takhzyro (lanadelumab injection) to treat people living with hereditary angioedema.
Takeda Canada is pleased to announce that it has completed its negotiations with the pan Canadian Pharmaceutical Alliance with a letter of intent regarding Takhyzro (lanadelumab injection) for routine prevention of hereditary angioedema attacks in adolescents and adults (12 years of age and older).
